Israeli drugmaker Teva says CEO has stepped down
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Tel Aviv
ISRAEL-BASED generic drugmaker Teva Pharmaceutical Industries Ltd said on Monday that chief executive Erez Vigodman was stepping down effective immediately and would be replaced on an interim basis by Yitzhak Peterburg, who has been chairman of Teva's board of directors.
Teva shares have performed poorly for more than a year and a half. They hit US$72 in late July of 2015 and closed at US$34.35 on the New York Stock Exchange on Monday, only to fall more than 2 per cent in extended trading after the latest management shakeup was announced.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
